Temporin-CEa

General Information


DCTPep ID  DCTPep00212

Peptide Name   Temporin-CEa

Sequence  FVDLKKIANIINSIF

Sequence Length  15

UniProt ID  Not available

PubChem CID  Not available

Origin  skin of the Chinese brown frog, Rana chensinensis

Type  Native peptide

Classification

  

ACP Tumor active peptide



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type IC50=12 µM MTT assay 24 h 1
MCF-7 Invasive breast carcinoma of no special type IC50=27.84 μM MTT assay 6 h 2
MCF-7 Invasive breast carcinoma of no special type IC50=31.78 μM MTT assay 1 h 2
MCF-7 Invasive breast carcinoma of no special type IC50=31.91 μM MTT assay 24 h 2
MCF-7 Invasive breast carcinoma of no special type IC50=34.5 μM MTT assay 48 h 2
HeLa Human papillomavirus-related endocervical adenocarcinoma IC50=36.31 μM MTT assay 24 h 2
BEL-7402 Human papillomavirus-related endocervical adenocarcinoma IC50=36.9 μM MTT assay 1 h 2
BEL-7402 Human papillomavirus-related endocervical adenocarcinoma IC50=37.1 μM MTT assay 6 h 2
BCaP-37 Human papillomavirus-related endocervical adenocarcinoma IC50=37.33 μM MTT assay 1 h 2
BCaP-37 Human papillomavirus-related endocervical adenocarcinoma IC50=38.39 μM MTT assay 48 h 2
BCaP-37 Human papillomavirus-related endocervical adenocarcinoma IC50=38.5 μM MTT assay 6 h 2
HeLa Human papillomavirus-related endocervical adenocarcinoma IC50=38.96 μM MTT assay 48 h 2
BEL-7402 Human papillomavirus-related endocervical adenocarcinoma IC50=38.98 μM MTT assay 24 h 2
BCaP-37 Human papillomavirus-related endocervical adenocarcinoma IC50=39.42 μM MTT assay 24 h 2
BEL-7402 Human papillomavirus-related endocervical adenocarcinoma IC50=40.16 μM MTT assay 48 h 2
HeLa Human papillomavirus-related endocervical adenocarcinoma IC50=40.6 μM MTT assay 6 h 2
HeLa Human papillomavirus-related endocervical adenocarcinoma IC50=43.87 μM MTT assay 1 h 2
SMMC-7721 Human papillomavirus-related endocervical adenocarcinoma IC50=44.92 μM MTT assay 1 h 2
SMMC-7721 Human papillomavirus-related endocervical adenocarcinoma IC50=46.73 μM MTT assay 6 h 2
SMMC-7721 Human papillomavirus-related endocervical adenocarcinoma IC50=47.73 μM MTT assay 48 h 2
SMMC-7721 Human papillomavirus-related endocervical adenocarcinoma IC50=50.32 μM MTT assay 24 h 2
A549 Lung adenocarcinoma IC50=52.09 μM MTT assay 48 h 2
A549 Lung adenocarcinoma IC50=52.82 μM MTT assay 1 h 2
A549 Lung adenocarcinoma IC50=53.12 μM MTT assay 6 h 2
A549 Lung adenocarcinoma IC50=53.31 μM MTT assay 24 h 2
MDA-MB-231 Breast adenocarcinoma IC50=54.95 μM MTT assay 48 h 2
BGC-823 Human papillomavirus-related endocervical adenocarcinoma IC50=55.16 μM MTT assay 6 h 2
BGC-823 Human papillomavirus-related endocervical adenocarcinoma IC50=56.47 μM MTT assay 1 h 2
MDA-MB-231 Breast adenocarcinoma IC50=57.94 μM MTT assay 24 h 2
LK-2 Lung squamous cell carcinoma IC50=58.32 μM MTT assay 1 h 2
NCI-H446 Lung small cell carcinoma; Small cell lung cancer IC50=59.45 μM MTT assay 1 h 2
MDA-MB-231 Breast adenocarcinoma IC50=60.38 μM MTT assay 6 h 2
LK-2 Lung squamous cell carcinoma IC50=61.57 μM MTT assay 48 h 2
BGC-823 Human papillomavirus-related endocervical adenocarcinoma IC50=61.63 μM MTT assay 24 h 2
LK-2 Lung squamous cell carcinoma IC50=61.73 μM MTT assay 6 h 2
HO-8910 Human papillomavirus-related endocervical adenocarcinoma IC50=62.84 μM MTT assay 1 h 2
BGC-823 Human papillomavirus-related endocervical adenocarcinoma IC50=63.2 μM MTT assay 48 h 2
MDA-MB-231 Breast adenocarcinoma IC50=63.26 μM MTT assay 1 h 2
LK-2 Lung squamous cell carcinoma IC50=63.4 μM MTT assay 24 h 2
HO-8910 Human papillomavirus-related endocervical adenocarcinoma IC50=64.75 μM MTT assay 24 h 2
NCI-H446 Lung small cell carcinoma; Small cell lung cancer IC50=64.81 μM MTT assay 6 h 2
NCI-H446 Lung small cell carcinoma; Small cell lung cancer IC50=65.29 μM MTT assay 48 h 2
HO-8910 Human papillomavirus-related endocervical adenocarcinoma IC50=66.55 μM MTT assay 48 h 2
HO-8910 Human papillomavirus-related endocervical adenocarcinoma IC50=66.68 μM MTT assay 6 h 2
NCI-H446 Lung small cell carcinoma; Small cell lung cancer IC50=67.66 μM MTT assay 24 h 2
HT-29 Colon adenocarcinoma IC50=88.91 μM MTT assay 1 h 2
HT-29 Colon adenocarcinoma IC50>100 μM MTT assay 6 h 2
HT-29 Colon adenocarcinoma IC50>100 μM MTT assay 24 h 2
HT-29 Colon adenocarcinoma IC50>100 μM MTT assay 48 h 2

Hemolytic Activity  Human erythrocytes: LD50=230 μM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep00212

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C83H135N19O21

Absent amino acids  CEGHMPQRTWY

Theoretical pI  8.59

Acidic residues  1

Basic residues  2

Polar residues  3

Molecular weight (Average)  1735.1

Molecular weight (Monoisotopic)  1734.01

Common amino acids  I

Net charge  1

Instability index (II)  17.29

Aliphatic index  156.00

Grand average of hydropathicity (GRAVY)  0.953

Half Life 
  1.1 hours (mammalian reticulocytes, in vitro).
  3 min (yeast, in vivo).
  2 min (Escherichia coli, in vivo).

Extinction coefficients 
  Should not be visible by UV spectrophotometry.

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 19341344

Title  Molecular cloning of cDNAs encoding antimicrobial peptide precursors from the skin of the Chinese brown frog, Rana chensinensis

Doi 10.2108/zsj.26.220

Year  2009

Literature 2

Pubmed ID 21871946

Title  Antitumor effects and cell selectivity of temporin-1CEa, an antimicrobial peptide from the skin secretions of the Chinese brown frog (Rana chensinensis)

Doi 10.1016/j.biochi.2011.08.011

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DCTPep is developed by Dr.Zheng's team.